Condition
Solid Tumor|Advanced Cancer|ColoRectal Cancer|Endometrial Cancer|Gastric Cancer|Hepatocellular Cancer|Nonsmall Cell Lung Cancer|Mesothelioma|Ovarian Cancer|Renal Cancer|Nasopharyngeal Cancer|Esophageal Cancer|Gastroesophageal Junction Adenocarcinoma
Estimated Enrollment: 50
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: CBT-501-01
Study First Received: January 30, 2017
Last Updated: March 30, 2017
Estimated Primary Completion Date: February 2018
Primary Outcome Measures:
Number of participants with treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.03) in patients with advance solid tumors|Determine the recommended Phase 2 dose and schedule|Area under the plasma concentration versus time curve (AUC)|Maximum plasma concentration|Time to reach Cmax|Overall Objective Response Rate|Duration of Response|Time to Response|Disease Control Rate|Progression Free Survival
Sponsors and Collaborators:
CBT Pharmaceuticals, Inc.|Novotech (Australia) Pty Limited
Website Link: https://ClinicalTrials.gov/show/NCT03053466
